{"id":"NCT02611778","sponsor":"Bioeq GmbH","briefTitle":"Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration","officialTitle":"Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-19","primaryCompletion":"2017-12","completion":"2018-06-06","firstPosted":"2015-11-23","resultsPosted":"2021-09-30","lastUpdate":"2021-09-30"},"enrollment":712,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Age-related Macular Degeneration (AMD)"],"interventions":[{"type":"BIOLOGICAL","name":"ranibizumab","otherNames":[]}],"arms":[{"label":"FYB201","type":"EXPERIMENTAL"},{"label":"Lucentis","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"FYB201","deltaMin":5.1,"sd":7.52},{"arm":"Lucentis","deltaMin":5.6,"sd":8.63},{"arm":"Total","deltaMin":5.4,"sd":8.1}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":33},"locations":{"siteCount":58,"countries":["Austria","Czechia","France","Germany","Hungary","Israel","Italy","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":238},"commonTop":["Neovascular age-related macular degeneration","Conjunctival haemorrhage","Nasopharyngitis","Intraocular pressure increased","Punctate keratitis"]}}